According to Zacks, “Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. “
Other research analysts have also issued reports about the company. Stephens lowered their price objective on Endologix from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Monday, March 23rd. BTIG Research lowered Endologix from a “buy” rating to a “neutral” rating in a research report on Monday, May 11th. Finally, ValuEngine cut Endologix from a “buy” rating to a “hold” rating in a research note on Tuesday, July 7th. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. Endologix presently has an average rating of “Hold” and a consensus target price of $3.40.
Endologix (NASDAQ:ELGX) last issued its quarterly earnings data on Monday, May 11th. The medical instruments supplier reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.13). The business had revenue of $28.51 million during the quarter, compared to analysts’ expectations of $28.50 million. Endologix had a negative return on equity of 63.96% and a negative net margin of 44.65%. On average, equities research analysts expect that Endologix will post -2.9 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in ELGX. Wedbush Securities Inc. acquired a new position in Endologix during the first quarter worth $26,000. King Wealth acquired a new position in Endologix during the first quarter worth $45,000. Invesco Ltd. lifted its stake in Endologix by 298.9% during the first quarter. Invesco Ltd. now owns 148,265 shares of the medical instruments supplier’s stock worth $102,000 after purchasing an additional 111,092 shares in the last quarter. NEA Management Company LLC acquired a new stake in shares of Endologix in the first quarter valued at $172,000. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of Endologix by 102.3% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 246,936 shares of the medical instruments supplier’s stock valued at $390,000 after acquiring an additional 124,894 shares in the last quarter. Institutional investors own 51.61% of the company’s stock.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.
Further Reading: Are all No-Load Funds Equal?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.